Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1613 | Indomethacin Wiki | 0.50 |
drug1723 | Ivermectin plus Nitazoxanide Wiki | 0.50 |
drug3370 | Tirofiban Injection Wiki | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
drug1311 | Fondaparinux Wiki | 0.50 |
drug1814 | Lopinavir-Ritonavir Drug Combination Wiki | 0.50 |
drug3650 | Zithromax Oral Product Wiki | 0.50 |
drug2117 | Natural Honey Wiki | 0.50 |
drug412 | Best Available Therapy Wiki | 0.50 |
drug145 | Acetylsalicylic acid Wiki | 0.50 |
drug2536 | Plasma Wiki | 0.29 |
drug776 | Clopidogrel Wiki | 0.29 |
drug3577 | Vitamin D3 Wiki | 0.20 |
drug1472 | Hydroxychloroquine Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D009767 | Obesity, Morbid NIH | 0.29 |
D016769 | Embolism and Thrombosis NIH | 0.25 |
D003924 | Diabetes Mellitus, Type 2 NIH | 0.14 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0005978 | Type II diabetes mellitus HPO | 0.14 |
HP:0001907 | Thromboembolism HPO | 0.10 |
HP:0002090 | Pneumonia HPO | 0.05 |
Navigate: Correlations HPO
There are 4 clinical trials
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has been discovered recently in December 2019 from wuhan city in China to spread in more than 40 countries allover the world. This disease has gain the attention of all nations after it has been stated as a pandemic by the World Health Organization (WHO) in March 12, 2020. Currently no treatment has been proved to be efficient in the treatment of infected patients by COVID-19. Natural honey has been demonstrated as potent antimicrobial in many research investigations and has been considered a good alternative for antiviral drugs for the treatment of some viral infections. The investigators aim to study the efficacy of natural honey in the treatment of COVID-19 patients in this randomized , multicenter, controlled trial, comparing honey in one arm to standard care in the other arm.
Description: Percentage of patients turned from positive to negative swaps at day 14
Measure: Rate of recovery from positive to negative swaps Time: 14 daysDescription: Number of days till no fever
Measure: Fever to normal temperature in days Time: 14 daysDescription: Number of days till lungs recovery in chest X ray or CT
Measure: Resolution of lung inflammation in CT or X ray Time: 30 daysDescription: mortality rate in each group at 30 days
Measure: 30 days mortality rate Time: 30 daysDescription: Number of days from initiation of intervention till changing of the swap test result from positive to negative
Measure: Number of days till reaching negative swab results Time: 30 daysResearch Background and Rationale In December 2019, a new infectious respiratory disease emerged in Wuhan, Hubei province, China. An initial cluster of infections was linked to Huanan seafood market, potentially due to animal contact. Subsequently, human-to-human transmission occurred and the disease, now termed coronavirus disease 19 (COVID-19) rapidly spread within China and all over the world. A novel coronavirus, SARS-coronavirus 2 (SARS-CoV-2), which is closely related to SARS-CoV, was detected in patients and is believed to be the etiologic agent of the new lung disease. The causative agent of the current COVID-19 pandemic, SARS-CoV-2, is a single stranded positive sense RNA virus that is closely related to severe acute respiratory syndrome coronavirus (SARS-CoV).
Description: COVID-19 PCR analysis
Measure: Number of Patients with COVID-19-negative PCR Time: within 10 daysDescription: improved breaths per minute for the patients
Measure: Number of patients with improved respiratory rate Time: within 30 daysDescription: Change in PaO2 in mmHg of the patients
Measure: Number of patients with improved PaO2 Time: within 30 daysDescription: Serum IL6 in pg/mL of the patients
Measure: Number of patients with normalized Serum IL6 Time: within 30 daysDescription: Serum TNFα in pg/mL of the patients
Measure: Number of patients with normalized Serum TNFα Time: within 30 daysDescription: Serum iron in microgram/dL of the patients
Measure: Number of patients with normalized Serum iron Time: within 30 daysDescription: Serum ferritinin microgram/L of the patients
Measure: Number of patients with normalized Serum ferritin Time: within 30 daysDescription: International normalized ratio "INR" for prothrombin time of 2
Measure: Number of patients with normalized International normalized ratio "INR" for prothrombin time Time: within 30 daysDescription: CBC for lymphocyte count in cells/microliter
Measure: Number of patients with normalized complete blood count "CBC" Time: within 30 daysDescription: Mortality rate [number of dead patients/total number of treated patients]
Measure: The Mortality rate among treated patients Time: within 30 daysThe purpose of this study is to assess whether lopinavir/ritonavir (or eventually other antiviral drugs) is effective at reducing the rate of hospitalization among confirmed COVID-19 cases treated as outpatients.
Description: Hospitalization associated with desaturation (SpO2 ≤92%) or death due to any cause
Measure: Hospitalization or death Time: 15 days following randomizationDescription: Death due to any cause
Measure: All-cause mortality Time: 15 days following randomizationDescription: Death due to any cause
Measure: All-cause mortality Time: 28 days following randomizationDescription: Length of time between randomization and hospitalization associated with desaturation (SpO2 ≤92%)
Measure: Time to hospitalization Time: 28 days following randomizationDescription: Total duration of hospitalization associated with desaturation (SpO2 ≤92%)
Measure: Length of hospitalization Time: 28 days following randomizationDescription: Proportion of participants admitted to an intensive care unit
Measure: Admission to intensive care Time: 28 days following randomizationDescription: Proportion of participants having an adverse event
Measure: Adverse events Time: 28 days following randomizationDescription: Proportion of participants having a serious adverse event
Measure: Serious adverse events Time: 28 days following randomizationIn response to the COVID-19 pandemic, weight management programs and metabolic surgery have been deferred to contain the virus. Quarantine and social distancing negatively impact dietary, exercise and psychological health of obese individuals. The study aims to evaluate the impact of social distancing measures on post-metabolic surgery patients compare to non-surgical obese patients and discuss potential strategies for management post COVID-19.
Description: 1 question asked about participants weight in kg before the lockdown; 1 question asked participants about weight in kg during lockdown
Measure: Weight Time: June2020-July2020Description: Participants were asked 1 question on how well blood sugar was controlled before the lock down. An ordinal scale was used: Very Poor, Poor, Reasonable, Good, Very Good. Participants were asked 1 question on how well blood sugar was controlled during the lock down. An ordinal scale was used: Very Poor, Poor, Reasonable, Good, Very Good.
Measure: Blood Sugar Control Time: June2020-July 2020Description: Participants were asked how often medication was missed before the lockdown with1 question using an ordinal scale: Never, Once in a while, Sometime, Usually, All the Time. Participants were asked how often medication was missed during the lockdown with1 question using an ordinal scale: Never, Once in a while, Sometime, Usually, All the Time.
Measure: Medical Adherence Time: June 2020-July2020Description: Participants were asked on the level of stress before the lockdown using a Likert scale of 1-10; with 1=not stressful at all; 10= extremely stressful. Participants were asked level of stress were during the lockdown using a Likert scale of 1-10; with 1=not stressful at all; 10= extremely stressful.
Measure: Stress level Time: June 2020-July2020Description: Participants were asked frequency of exercise before the lockdown on a ordinal scale ranging from less than 1 time a week; Once a week; 2-3 times a week;4-5 times a week; More than 5 times a week. Participants were asked frequency of exercise during the lockdown on a ordinal scale ranging from less than 1 time a week; Once a week; 2-3 times a week;4-5 times a week; More than 5 times a week
Measure: Physical Activity Level Time: June2020-July 2020Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports